Hori S, Kitagawa S, Iwata H, Ochiai T, Isono K, Hamaoka T, Fujiwara H
Biomedical Research Center, Osaka University Medical School, Japan.
J Exp Med. 1992 Jan 1;175(1):99-109. doi: 10.1084/jem.175.1.99.
The intravenous sensitization of C57BL/6 (B6) mice with class I H-2-disparate B6-C-H-2bm1 (bm1) spleen cells results in almost complete abrogation of anti-bm1 CD8+ helper (proliferative and interleukin 2-producing) T cell (Th) activities. Although an appreciable portion of CD8+ cytotoxic T lymphocyte (CTL) precursors themselves remained after this regimen, such a residual CTL activity was eliminated after the engrafting of bm1 grafts, and these grafts exhibited prolonged survival. In contrast, the intravenous sensitization with (bm1 x B6-C-H-2bm12 [bm12])F1 cells instead of bm1 cells failed to induce the prolongation of bm1 graft survival as well as bm12 and (bm1 x bm12)F1 graft survival. In the (bm1 x bm12)F1-presensitized B6 mice before as well as after the engrafting of bm1 grafts, anti-bm1 CTL responses that were comparable to or slightly stronger than those observed in unpresensitized mice were induced in the absence of anti-bm1 Th activities. bm1 graft survival was also prolonged by intravenous presensitization with a mixture of bm1 and bm12 cells but not with a mixture of bm1 and (bm1 x bm12)F1 cells. The capacity of CD4+ T cells to reject bm12 grafts was eliminated by intravenous presensitization with antigen-presenting cell (APC)-depleted bm12 spleen cells. However, intravenous presensitization with APC-depleted (bm1 x bm12)F1 cells failed to induce the prolongation of bm1 graft survival under conditions in which appreciably prolonged bm12 graft survival was induced. More surprisingly, bm1 graft survival was not prolonged even when the (bm1 x bm12)F1 cell presensitization was performed in CD4+ T cell-depleted B6 mice. This contrasted with the fact that conventional class I-disparate grafts capable of activating self Ia-restricted CD4+ as well as allo-class I-reactive CD8+ Th exhibited prolonged survival in CD4+ T cell-depleted, class I-disparate cell-presensitized mice. These results indicate that: (a) intravenous presensitization with class I- and II-disparate cells fails to reduce anti-allo-class I rejection responses that would otherwise be eliminated using only class I-disparate cells; (b) such failure is generated according to the coexpression of both classes of alloantigens on a single cell as tolerogen; and (c) allo-class II antigens coexpressed on tolerogen function to activate CD4+ as well as non-CD4+ Th leading to the generation of anti-class I effector T cell responses.
用I类H - 2不同的B6 - C - H - 2bm1(bm1)脾细胞对C57BL / 6(B6)小鼠进行静脉致敏,几乎可完全消除抗bm1 CD8 +辅助(增殖性和产生白细胞介素2的)T细胞(Th)活性。尽管在此方案后仍有相当一部分CD8 +细胞毒性T淋巴细胞(CTL)前体自身保留,但在植入bm1移植物后,这种残留的CTL活性被消除,并且这些移植物存活时间延长。相比之下,用(bm1×B6 - C - H - 2bm12 [bm12])F1细胞而非bm1细胞进行静脉致敏,未能诱导bm1移植物存活时间延长,也未能诱导bm12和(bm1×bm12)F1移植物存活时间延长。在植入bm1移植物之前和之后,在(bm1×bm12)F1预致敏的B6小鼠中,在没有抗bm1 Th活性的情况下,诱导出了与未预致敏小鼠中观察到的相当或略强的抗bm1 CTL反应。用bm1和bm12细胞的混合物进行静脉预致敏也可延长bm1移植物存活时间,但用bm1和(bm1×bm12)F1细胞的混合物则不能。用去除抗原呈递细胞(APC)的bm12脾细胞进行静脉预致敏可消除CD4 + T细胞排斥bm12移植物的能力。然而,在可诱导bm12移植物明显延长存活时间的条件下,用去除APC的(bm1×bm12)F1细胞进行静脉预致敏未能诱导bm1移植物存活时间延长。更令人惊讶的是,即使在CD4 + T细胞缺失的B6小鼠中进行(bm1×bm12)F1细胞预致敏,bm1移植物存活时间也未延长。这与以下事实形成对比:能够激活自身Ia限制的CD4 +以及同种I类反应性CD8 + Th的传统I类不同移植物,在CD4 + T细胞缺失、I类不同细胞预致敏的小鼠中存活时间延长。这些结果表明:(a)用I类和II类不同细胞进行静脉预致敏不能降低抗同种I类排斥反应,而仅用I类不同细胞进行预致敏则可消除该反应;(b)这种失败是由于两类同种抗原在单个细胞上作为耐受原共同表达所致;(c)在耐受原上共同表达的同种II类抗原起到激活CD4 +以及非CD4 + Th的作用,从而导致产生抗I类效应T细胞反应。